Odonate Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Odonate Therapeutics's estimated annual revenue is currently $9.3M per year.
- Odonate Therapeutics's estimated revenue per employee is $202,174
- Odonate Therapeutics's current valuation is $43.1M. (January 2022)
- Odonate Therapeutics has 46 Employees.
- Odonate Therapeutics grew their employee count by -78% last year.
Odonate Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Odonate Therapeutics?
Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.keywords:N/A
Number of Employees
Employee Growth %
Odonate Therapeutics News
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Odonate Therapeutics, Inc. ODTC | 12 hours ago. Wilmington, Delaware--(Newsfile Corp. - April 19,...
NEW YORK--(BUSINESS WIRE)--Mar 22, 2021-- Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore ...
Shares of Odonate Therapeutics, Inc. (ODT) have been trending lower over the past five bars, revealing bearish momentum for the shares, ...
Shares of Odonate Therapeutics, Inc. (:ODT) have been on a recent steady downtrend, causing some worry for shareholders. Investors may be ...
Carillon Tower Advisers Inc. purchased a new stake in shares of Odonate Therapeutics Inc (NASDAQ:ODT) during the 2nd quarter, according ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|